Skip to content

AbCellera Biologics Inc. ABCL Occupancy and Related Charges

Occupancy and Related Charges at other companies

ADMA Biologics logo
ADMA BiologicsADMA
$500K-16.7%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX

Other financials

Income statement

See full
Revenue$8.3M+96.3%
Operating income-$57.5M+8.2%
Net income-$43.2M+5.4%
EPS (diluted)-$0.14+6.7%

Balance sheet

See full
Cash & equivalents$102.1M-44.6%
Total debt$140.2M+107%
Total equity$938.1M-8.3%
Total assets$1.3B-2.8%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$3.8M-64.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.84B+59.2%

Profitability

See full
Operating margin-267.6%-120pp
Net margin-181.7%-77.9pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-14.7%-0.8pp
Debt / equity0.1×+0.1×
Current ratio14.1×+3.9×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseExpense.

The official record: AbCellera Biologics Inc.’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s occupancy and related charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbCellera Biologics Inc.'s occupancy and related charges?
AbCellera Biologics Inc. (ABCL) reported occupancy and related charges of $2.83M in Q4 2025.
How has AbCellera Biologics Inc.'s occupancy and related charges changed year-over-year?
AbCellera Biologics Inc.'s occupancy and related charges increased by 24.2% year-over-year, from $2.28M to $2.83M.
What is the long-term trend for AbCellera Biologics Inc.'s occupancy and related charges?
Over 2 years (2023 to 2025), AbCellera Biologics Inc.'s occupancy and related charges has grown at a 9.1% compound annual growth rate (CAGR), from $9.5M to $11.3M.